AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Idiopathic Pulmonary Fibrosis Market Review 2016-2019 and $5.7+ Billion Industry Forecast to 2026 - ResearchAndMarkets.com

November 20, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 20, 2019--

The “Global Idiopathic Pulmonary Fibrosis Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.

The Idiopathic Pulmonary Fibrosis market is expected to reach $5,733.24 million by 2026 growing at a CAGR of 13.5% from 2018 to 2026.

Factors such as the rise in geriatric population, a surge in cigarette smoking population and an increase in a number of patients suffering from idiopathic pulmonary fibrosis are fuelling the market growth. However, unavailability of proper treatment options is restricting the market growth.

Based on the route of administration, the parenteral route segment is to be the most preferred route of drug administration during the forecast period. Drugs administered by the parenteral route bypass the first-pass metabolism and enter the bloodstream directly. This helps in the fast delivery of drugs or nutrients into the body.

The key vendors mentioned are Biogen, Boehringer Ingelheim, MediciNova, Inc., Afferent Pharmaceuticals, Baxter, Bristol-Myers Squibb, F. Hoffmann-La Roche, Promedior, Prometheus Laboratories, Amgen, FibroGen, Merck, Prometic Life Sciences, Galapagos, Cipla Inc., Asahi Kasei Corporation, and Sanofi S.A.

Key Questions Answered in this Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Idiopathic Pulmonary Fibrosis Market, By Type

5.1 Introduction

5.2 Antifibrotic Agents

5.3 Systemic Corticosteroids

5.4 Immunosuppressant Drugs

5.5 Tyrosine Kinase Inhibitors

6 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type

6.1 Introduction

6.2 Nintedanib

6.3 Pirfenidone

7 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration

7.1 Introduction

7.2 Parenteral

7.3 Oral

8 Global Idiopathic Pulmonary Fibrosis Market, By Application

8.1 Introduction

8.2 Malaria

8.3 Arrhythmias

8.4 Other Applications

9 Global Idiopathic Pulmonary Fibrosis Market, By End User

9.1 Introduction

9.2 Clinics

9.3 Academic and Research Organizations

9.4 Hospitals

9.5 Ambulatory Surgical Centers

9.6 Other End Users

10 Global Idiopathic Pulmonary Fibrosis Market, By Geography

10.1 Introduction

10.2 North America

10.3 Europe

10.4 Asia Pacific

10.5 South America

10.6 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape

12.1 Biogen

12.2 Boehringer Ingelheim

12.3 MediciNova Inc.

12.4 Afferent Pharmaceuticals

12.5 Baxter

12.6 Bristol-Myers Squibb

12.7 F. Hoffmann-La Roche

12.8 Promedior

12.9 Prometheus Laboratories

12.10 Amgen

12.11 FibroGen

12.12 Merck

12.13 Prometic Life Sciences

12.14 Galapagos

12.15 Cipla Inc.

12.16 Asahi Kasei Corporation

12.17 Sanofi S.A.

For more information about this report visit https://www.researchandmarkets.com/r/f10g4g

View source version on businesswire.com:https://www.businesswire.com/news/home/20191120005839/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/20/2019 01:49 PM/DISC: 11/20/2019 01:49 PM

http://www.businesswire.com/news/home/20191120005839/en